Here's Why Solventum (SOLV) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 10, 2026

Solventum Q2 Earnings Call Highlights

Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.

MarketBeat • Aug 9, 2026

Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates

SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.

Zacks Investment Research • Aug 6, 2026

Solventum to hive off healthcare software business, raises profit forecast

Solventum , one of the largest providers of hospital consumables and sterilization devices, said on Wednesday it ​is planning to separate its health information systems ‌business as part of its ongoing turnaround strategy.

Reuters • Aug 5, 2026

Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript

Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Solventum Reports Second Quarter 2026 Financial Results

Reported sales increased 2.2%; organic sales increased 9.5% Announces intent to separate its Health Information Systems business segment Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.

PRNewsWire • Aug 5, 2026

Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Aug 5, 2026

Solventum (SOLV) Q2 Earnings and Revenues Top Estimates

Solventum (SOLV) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.69 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Solventum Announces Intent to Separate its Health Information Systems Business

Strengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase transformation strategy Positions Health Information Systems, a leading, scaled, healthcare software business, to accelerate its strategic vision and growth agenda as a separate entity Unlocks shareholder value and enables targeted investment supporting innovation and growth across both businesses EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced its intention to pursue a separation of its Health Information Systems business as part of the company's ongoing portfolio optimization strategy.

PRNewsWire • Aug 5, 2026

What's in Store for These 4 Healthcare Companies This Earnings Season?

McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.

Zacks Investment Research • Aug 4, 2026